Pharmacogenetic polymorphisms affecting bisoprolol response by Castaño Amores, Celia et al.
Biomedicine & Pharmacotherapy 142 (2021) 112069
Available online 27 August 2021
0753-3322/© 2021 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Pharmacogenetic polymorphisms affecting bisoprolol response 
Celia Castaño-Amores a,2, Xando Díaz-Villamarín a,b,*,1,2, Ana María Pérez-Gutiérrez c, 
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A B S T R A C T   
β-blockers are commonly prescribed to treat multiple cardiovascular (CV) diseases, but, frequently, adverse drug 
reactions and intolerance limit their use in clinical practice. Interindividual variability in response to β-blockers 
may be explained by genetic differences. In fact, pharmacogenetic interactions for some of these drugs have been 
widely studied, such as metoprolol. But studies that explore genetic variants affecting bisoprolol response are 
inconclusive, limited or confusing because of mixed results with other β-Blockers, different genetic poly-
morphisms observed, endpoint studied etc. Because of this, we performed a systematic review in order to find 
relevant genetic variants affecting bisoprolol response. We have found genetic polymorphism in several genes, 
but most of the studies focused in ADRB variants. The ADRB1 Arg389Gly (rs1801253) was the most studied 
genetic polymorphism and it seems to influence the response to bisoprolol, although studies are inconclusive. 
Even, we performed a meta-analysis about its influence on systolic/diastolic blood pressure in patients treated 
with bisoprolol, but this did not show statistically significant results. In conclusion, many genetic polymorphisms 
have been assessed about their influence on patientś response to bisoprolol and the ADRB1 Arg389Gly 
(rs1801253) seems the most relevant genetic polymorphism in this regard but results have not been confirmed 
with a meta-analysis. Our results support the need of further studies about the impact of genetic variants on 
bisoprolol response, considering different genetic polymorphisms and conducting single and multiple SNPs 
analysis, including other clinical parameters related to bisoprolol response in a multivariate study.   
1. Introduction 
Bisoprolol is a highly selective β1-blocker approved for the treatment 
of hypertension, heart failure (HF) and ischemic heart disease [1]. 
Beta-receptors are G-protein-coupled receptors (Gs alpha subunit) 
which action are mediated by the cyclic adenosine monophosphate 
(cAMP) and cAMP-dependent protein kinase that increases calcium ion 
concentration with an inotropic effect on cardiomyocytes. Bisoprolol 
and other β-blockers inhibit this process and exert their antiarrhythmic 
action (Fig. 1). 
In the ESC EUROASPIRE V (European action on secondary and pri-
mary prevention by intervention to reduce events – European Society of 
Cardiology) registry of patients with coronary diseases, β-blockers were 
prescribed to 81% of patients [3]. Data from the CLARIFY registry 
(Prospective observational longitudinal registry of patients with stable 
coronary artery disease) show that β-blockers were prescribed in 77% of 
western/central Europe and 87% in eastern European population. Even 
though, heart rate control is not addressed adequately [4]. 
In the TRECE registry (Treatment of coronary artery disease in 
Spain), including patients with coronary artery disease (CAD) in Spain, 
atenolol (43.9%) was the most prescribed β-blocker followed by biso-
prolol (30.9%) and both groups of patients had significantly higher 
prevalence of resting heart rate (RHR) < 70 bpm, compared to those 
with metoprolol, carvedilol or propranolol [5]. 
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In a recent study, Taborsky et al. analyzed the use of β-blockers in HF 
patients in the Czech Republic between 2012 and 2018. Thus, meto-
prolol and bisoprolol were the most prescribed β-blockers. In particular, 
bisoprolol prescription changed among those years, from 20.3% in 2012 
to 28% in 2018 [6]. In particular in Spain and our hospital, bisoprolol is 
largely the most prescribed β-blocker. 
Bisoprolol is administered orally with 90% of bioavailability and 
50% of the dose is metabolized by hepatic clearance [1]. An in vitro 
study demonstrated that CYP3A4 and CYP2D6 enzymes are enrolled in 
the oxidation of both bisoprolol enantiomers [7]. 
Anyway, β-blockers are largely prescribed, its use has been widely 
studied since its discovery in 1960s, new mechanisms of action are still 
revealed [8] and they are well stablished for various cardiovascular (CV) 
diseases, but, adverse effects and patientś intolerance lead to stop the 
treatment [9]. 
Interindividual differences about patientś response to these drugs 
have been found. The cytochrome P450 (CYP) isoenzymes, especially 
CYP2D6, have shown to affect the metabolism of several drugs, thus 
genetic variants in the gene encoding this enzyme might affect the 
response to β -blockers, among other drugs [10]. 
Over the years, pharmacogenetics (PGx) studies have gained value in 
the management of CV diseases, especially for the purpose of achieving 
target dose of drugs, thus, avoiding adverse drug reactions [11]. 
Regarding β -blockers, finding single nucleotide polymorphisms (SNPs) 
that would predict responsiveness to treatment, and the study of its 
clinical impact on undesirable effects is determinant to optimize CV 
therapies. Regarding bisoprolol, many genetic variants have been 
assessed about their possible PGx association, some of them with 
inconclusive results [12]. 
β-Adrenoceptors (β-AR) are targets of endogenous catecholamines 
Fig. 1. Molecular mechanism of beta-receptors and β-blockers affinity [2].  
Fig. 2. Bibliography search strategy.  
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and agonist or antagonist drugs. They are particularly polymorphic re-
ceptors extensively investigated to assess an association with interindi-
vidual variability in β -blockers response or risk of disease [13]. 
Most of the studies have focused on genes coding for β1 and β2-AR, 
especially two SNPs in β1-AR gene (ADRB1): rs1801252 (Ser49Gly) and 
rs1801253 (Arg389Gly); and rs1042713 (Gly16Arg), rs1042714 
(Gln27Glu) in β2-AR gene (ADRB2) [11,13]. 
In the ADRB1, rs1801252 AG and GG genotypes are related to a 
higher risk of major adverse events (MACE) in patients treated with 
β-blockers [14]. As well, ADRB1 (rs1801252) AA carriers have been 
described to response better to metoprolol than AG carriers, but this 
association might also be influenced by rs1801253(Arg389Gly) poly-
morphism [15]. In contrast, the AA genotype for this SNP was not 
related to blood pressure reduction in hypertensive patients treated with 
bisoprolol [16]. 
In patients with CAD, carrying the ADRB1(rs1801253) CC genotype 
is associated with lower catecholamines required doses compared with 
CG or GG genotype [17]. Johnson et al. also described better diastolic 
blood pressure (BP) response to metoprolol in patients with the CC ge-
notype and Terra et al. found an association of this SNP with improve-
ment in left ventricular ejection fraction (LVEF) [15,18]. Parvez et al. 
had reported contradictory results in patients with atrial fibrillation 
describing better response to atenolol, metoprolol or carvedilol in 
ADRB1 (rs1801253) CG or GG carriers [19]. 
On the other hand, several studies concluded that CC genotype of this 
SNP is not associated with better response to β-blockers, including 
metoprolol, carvedilol and atenolol, in patients with essential hyper-
tension or HF [20]. The average dose of bisoprolol did not differ between 
CC genotype and CG/GG genotype in patients with CAD [21]. Related to 
heart rate, Rau et al. associated CC genotype with a lower response in 
patients with HF treated with carvedilol and they found no genetic as-
sociation in those patients treated with bisoprolol [22]. The absence of 
PGx interaction between ADRB1 Arg389Gly genotype (rs1801253) and 
β-blockers was previously reported by de Groote et al. in patients with 
HF [23]. 
In the ADRB2 gene, rs1042714GG genotype is associated with 
greater response to carvedilol in HF patients compared to CC or CG 
genotype but other studies did not find significant associations [23–25]. 
Recently, CC genotype has been related to increased heart rate lowering 
effect, so better response to atenolol or metoprolol in patients with 
European ancestry [26]. 
As mentioned before, variability in pharmacokinetics caused by 
impaired hepatic metabolism is of main interest to select the adequate 
β-blocker for each patient. In this regard, CYP2D6*4 and CYP2D6*10 are 
the most important studied alleles. CYP2D6*3/*4/*5/*6 carriers are 
known of having reduced metabolism of metoprolol [27]. The 
CYP2D6*4 (rs3892097) T allele has been associated with higher 
lowering effect of metoprolol on heart rate and BP compared to C allele 
[28]. CYP2D6*10 (100C > T) (rs1065852) GG genotype was associated 
with lower heart rate in patients with HF and percutaneous coronary 
intervention after metoprolol treatment compared to AA or AG genotype 
[29]. It has also been described a reduced metabolism of carvedilol in 
patients with angina related to CYP2D6*10 allele [30]. 
Another interesting studied gene linked to CYP metabolism is the 
ACY3, encoding the amino acylase 3 protein. The C allele (rs2514036) 
seems to be associated with better diastolic and systolic BP reduction in 
hypertensive patients treated with bisoprolol or atenolol compared to T 
allele [31], but Hiltunen et al. described contradictory results in hy-
pertensive men with increased response to bisoprolol in T allele carriers 
compared to C allele [32]. 
Genetic variants affecting the response to β-blockers have been 
identified. Even, for metoprolol, its drug label includes pharmacogenetic 
information reporting the association with CYP2D6 variants. In this re-
gard, patients carrying CYP2D6 no function variants, translated into 
CYP2D6 intermediate/poor metabolizer phenotypes, have been related 
to a lower conversion of metoprolol to its inactive metabolites, thus with 
higher rates of bradycardia, and, pharmacogenetic dosing guidelines 
from the Dutch Pharmacogenomics Working Group (DPWG) recom-
mend to increase the dose in smaller steps and/or prescribe no more 
than 25% of the standard dose if gradual reduction in heart rate is 
desired, or in the event of symptomatic bradycardia (Level of evidence 
1 A: variant-drug combinations that have variant-specific prescribing 
guidance available). On the other hand, ultra-rapid metabolizers, car-
rying CYP2D6 increased function alleles, have been associated with an 
increased conversion of metoprolol to inactive metabolites and DPWG 
guidelines recommend to use the maximum dose for the relevant indi-
cation as a target dose or, if the effectiveness is still insufficient, to in-
crease the dose based on effectiveness and side effects to 2.5 times the 
standard dose or select an alternative. 
Regarding bisoprolol, most of these drug-gene interactions have been 
reported as Level 3 of evidence (Variant-drug combinations with a low 
level of evidence supporting the association), as they are based on a 
single significant (not yet replicated) study or annotation evaluated in 
multiple studies but lacking clear evidence of an association [33]. 
Moreover, there is a wide heterogeneity in PGx studies of β-blockers. 
While some of them analyze genetic variants associated with response to 
various β-blockers, others have focused on a specific β-blocker in a single 
cohort of patients with a certain cardiovascular pathology, based on 
intrinsic and pharmacokinetic differences among β-blockers [34]. 
Thus, the aim of this study is to explore genetic variants affecting 
bisoprolol response, performing a systematic review and a meta- 
analysis. 
2. Material and methods 
2.1. Search strategy and inclusion/exclusion criteria 
A systematic review about genetic variants affecting the response to 
bisoprolol was performed. In order to find relevant manuscripts about 
this topic we performed a search in Pubmed on 15th January 2021 using 
MESH terms in the following argument: (“Bisoprolol” OR “Metoprolol” 
OR “Adrenergic Beta antagonist”) AND (“Pharmacogenetic” OR “SNP” 
OR Polymorphism”). 
The publications found in the initial search were included for review 
according to the following inclusion/exclusion criteria:  
1. Manuscripts written in English (only) were included.  
2. Manuscripts assessing the association of genetic variants with the 
illness and not related to bisoprolol response were excluded.  
3. Manuscripts studying the association of any genetic variant with 
bisoprolol in vitro or non-humans were excluded.  
4. Reports, comments and editorials were excluded.  
5. Manuscripts about genetic variants affecting β -Blockers response 
without reporting results about bisoprolol treated patients were 
excluded.  
6. Only manuscripts about genetic variants influencing bisoprolol 
response in human patients were included. 
First, we checked all abstract titles looking for publications not 
written in English. Then, we extensively read abstracts and/or complete 
manuscripts in order to identify those publications meeting the inclu-
sion/exclusion criteria. We also checked all the review articles found in 
the initial search with the aim of identifying other publications meeting 
the inclusion/exclusion criteria. Finally, we manually checked the pro-
vided literature on PharmGKB about genetic variants affecting biso-
prolol response to verify that we had not excluded any relevant 
publication related to the topic of this systematic review. 
2.2. Data extraction and quality assessment 
Two different researchers carried out the search strategy. In case of 
discrepancies, another researcher blinded for the decision from these 2 
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researchers, performed an independent evaluation and took the final 
inclusion/exclusion decision. 
Regarding those considered for inclusion manuscripts, we performed 
a quality assessment using the Newcastle–Ottawa quality assessment 
scale (NOS) [35]. About this, we judged each study on three categories 
(selection, comparability, and exposure) and eight items, up to nine 
“stars/points”, as the top score. Finally, considered to inclusion manu-
scripts with NOS score below five points were excluded. We obtained the 
following information from the included studies: author, reference SNP 
(rs), gene, SNP, minor allele frequency (MAF), genotypes distribution, 
ethnicity, treatment strategy, diagnosis, follow-up time, study endpoint 
and results. 
2.3. Meta-analysis 
Among all the publications found, we included in the meta-analysis 
those patients treated with bisoprolol, without exclusions regarding 
diagnosis, treatment strategy or ethnicity. Every genetic variant assessed 
to be related to bisoprolol response was included, and all the efficacy or 
toxicity parameters used to evaluate the association between genetic 
variants and patientś drug response were recorded and considered for 
meta-analysis. 
We conducted a random-effects meta-analysis in recessive, domi-
nant, codominant and over-dominant models for the G risk allele in 
order to assess the association between the ADRB1 A389G (rs1801253) 
and treatment response to bisoprolol, as it was the only genetic variant 
meeting the meta-analysis criteria. 
For each primary study, we calculated the effect size as the stan-
dardized difference in means between the two groups being compared. A 
random-effects meta-analysis was chosen due to the variability in 
methods across the primary studies. Heterogeneity between primary 
studies was assessed using the I2 statistic [36]. We used R statistics 
software, version 3.6.2, with the package “meta” to conduct the 
meta-analysis (https://CRAN.R-project.org/package=meta). 
We used Harbord′s test in order to quantitatively assess publication 
bias, considering p-value < 0.1 as significant statistical publication bias. 
3. Results 
In the initial search we found 1003 publications. Based on their titles 
we excluded 65 not written in English. The abstracts of the remaining 
938 publications were examined and 235 were excluded because of 
being reports, comments, editorials or reviews. We also excluded 212 
publications because of being in vitro or no-human studies, or exploring 
genetic variants related to different pathologies and not to β -blockers 
response. 
Finally, we found 491 publications studying the association between 
different SNPs and the response to β-blockers, but most of them 
(n = 478) exploring the association with different drugs to bisoprolol or 
doing this without reporting differentiated results about bisoprolol. 
After checking publications included in reviews found in the initial 
search and those included in PharmGKB as research articles about 
pharmacogenetics of bisoprolol, we did not find discrepancies, so we 
considered we had performed the bibliography search properly. 
This way 13 research articles were selected as publications analyzing 
genetic variants associated with bisoprolol response (Tables 1 and 2). 
Among them, no one was scored below five points with the NOS scale, 
and we did not find evidence of publication bias after Harbord́s test. 
Table 1 
Genetic variants and population characteristics of research articles studying genetic variants influencing bisoprolol response in human patients.  
Author refSNP (rs) Gen SNP (Location) MAF Genotype mm/Mm/MM Ethnicity Patients Follow-up 
Zaugg et al. [21] rs1801252 ADRB1 Ser49Gly 0111 1/41/147 Switzerland CAD 12 m  
rs1801253 ADRB1 Arg389Gly 0198 27/47/112 Switzerland CAD 12 m  
rs1042713 ADRB2 Gly16Arg 0251 25/70/94 Switzerland CAD 12 m  
rs1042714 ADRB2 Gln27Glu 0243 26/66/97 Switzerland CAD 12 m 
Mohammed Alkreathy et al. [37] rs1080985 CYP2D6 C1496G 0257 18/19/70 South Arabia CD –  
rs1065852 CYP2D6 C100T 0,00 0/0/99 South Arabia CD  
Fedorinov et al. [38] rs3892097 CYP2D6 G1846A 0,09 0/6/26 Russian/Yakut CAD –  
rs1065852 CYP2D6 C100T 0,15 0/10/22 Russian/Yakut CAD  
Lee et al. [39] rs1801253 ADRB1 Arg389Gly 0,18 5/25/53 Korea HF 12 m  
rs1042713 ADRB2 Gly16Arg 0,33 14/41/28 Korea HF 12 m  
rs1042714 ADRB2 Gln27Glu 0,09 1/15/67 Korea HF 12 m 
Rau et al. [22] rs1801252 ADRB1 Ser49Gly – – Caucasian HF (SR/AF) 4 weeks  
– CYP2D6 – – – Caucasian HF (SR/AF) 4 weeks  
rs1801253 ADRB1 Arg389Gly 0,23 23/101/140 Caucasian HF (SR/AF) 4 weeks 
Suonsyrja et al. [40] rs4961 ADD1 Gly460Trp 0,21 13/78/117 Finnish EH 4 weeks  
– ACE ACE I/D 0,34 37/105/66 Finnish EH 4 weeks  
rs699 AGT Met235Thr 0,31 35/78/95 Finnish EH 4 weeks  
rs5186 AGTR1 1166A/C 0,13 5/52/151 Finnish EH 4 weeks 
Donner et al.* [41] rs17367504 MTHFR 236 + 160T > C 0,14 3/51/152 Finnish EH 4 weeks  
rs9815354 ULK4 750 + 12715C > T 0,24 18/83/143 Finnish EH 4 weeks 
Hiltunen et al. [32] ^ ACY3 ^ – – Finnish EH 4 weeks 
de Groote et al. [23] rs1801252 ADRB1 Ser49Gly 0,14 3/34/93 Caucasian Stable HF 30 m  
rs1801253 ADRB1 Arg389Gly 0,24 15/48/67 Caucasian Stable HF 30 m  
rs1042713 ADRB2 Gly16Arg 0,29 20/57/53 Caucasian Stable HF 30 m  
rs1042714 ADRB2 Gln27Glu 0,31 25/57/48 Caucasian Stable HF 30 m  
rs1800888 ADRB2 Thr164Ile 0,02 0/5/125 Caucasian Stable HF 30 m 
Bruck et al. [42] † rs1801253 ADRB1 Arg389Gly 0,2 8/0/10 UK Normal health 2 days 
de Groote et al. [43] – ACE ACE I/D 0,28 20/53/57 Caucasian HF 30 m 
Gong et al. [44] rs12346562 PTPRD 11018077C > A 0.27 – Finnish EH –  
rs7640608 OTOL1 161760608A > G 0.05 – Finnish EH – 
Suonsyrja et al. [16] rs1801252 ADRB1 Ser49Gly 0,14 7/58/143 Finnish EH 4 weeks  
rs1801253 ADRB1 Arg389Gly 0,2 13/73/122 Finnish EH 4 weeks  
rs1042713 ADRB2 Gly16Arg 0,34 39/103/66 Finnish EH 4 weeks  
rs1042714 ADRB2 Gln27Glu 0,3 30/95/83 Finnish EH 4 weeks 
refSNP: Reference single nucleotide polymorphism; MAF: Minor Allele Frequency; mm: number of patients with recessive homozygous genotype; Mm: Heterozygous 
genotype; MM: Dominant homozygous genotype; CAD: Coronary Artery Disease; CD: Cardiac Disease; HF (SR/AF): Heart Failure (Sinus rhythm/Atrial fibrillation); EH: 
Essential hypertension; “- ”means “Data not shown in the original article”. *Only shows genes with statistically significant related results, see the original publication to 
know all the studied genes and variants. ^ Several SNPs were studied, see the original publication; † Patients treated with bisoprolol and dobutamine. 
C. Castaño-Amores et al.                                                                                                                                                                                                                      
Biomedicine & Pharmacotherapy 142 (2021) 112069
5
Table 2 
Genetic variants, related bisoprolol efficacy endpoints and resulting p-values of included articles.  
Study n Gen SNP (Location) Related endpoint p-valor 




186 ADRB1 Arg389Gly  p = 0,01  
189 ADRB2 Gly16Arg  Data not 
shown  
189 ADRB2 Gln27Glu  Data not 
shown 
Mohammed Alkreathy 
et al. [37] 
107 CYP2D6 C1496G Blood pressure/Heart rate/[Bisoprolol] Data not 
shown  
107 CYP2D6 C100T  Data not 
shown 
Fedorinov et al. [38] 32 CYP2D6 G1846A Dose titrated bisoprolol p = 0029  
32 CYP2D6 C100T  p = 0244  
32 CYP2D6 G1846A/C100T  p = 0,03 
Lee et al. [39]+ 83 ADRB1 Arg389Gly Heart rate change (6 months) p = 0,43     
Systolic BP P = 0,41     
Diastolic BP P = 0,90     
Dose of bisoprolol needed p = 0022     
Left ventricular volume p = 0,26     
B-natriuretic peptide p = 0005     
Readmission/mortality (1 year) p = 0162  
83 ADRB2 Gly16Arg Data not shown Data not 
shown  
83 ADRB2 Gln27Glu Data not shown Data not 
shown 
Rau et al. [22] 264 ADRB1 Ser49Gly Heart rate lowering difference Data not 
shown  
264 CYP2D6 –  Data not 
shown  
264 ADRB1 Arg389Gly  p > 0,08 
Suonsyrja et al. [40] 208 ADD1 Gly460Trp Ambulatory BP (Systolic/diastolic) p = 0,03/ 
p = 0,13     
Office BP (Systolic/diastolic) p = 0,61/ 
p = 0,49  
208 ACE ACE I/D Ambulatory BP (Systolic/diastolic) p = 0,56/ 
p = 0,36     
Office BP (Systolic/diastolic) p = 0,33/ 
p = 0,29  
208 AGT Met235Thr Ambulatory BP (Systolic/diastolic) p = 0,98/ 
p = 0,48     
Office BP (Systolic/diastolic) p = 0,72/ 
p = 0,94  
208 AGTR1 1166A/C Ambulatory BP (Systolic/diastolic) p = 0,82/ 
p = 0,71     
Office BP (Systolic/diastolic) p = 0,82/ 
p = 0,38 
Donner et al. [41]* 208 MTHFR rs2514036 Systolic BP (multivariate/univariate)  
Diastolic (multivariate/ 
univariate) 
p = 0.21/0.002, 
p = 0.17/0.001      
208 ULK4 750 + 12715C > T Systolic BP (multivariate/univariate)  
Diastolic (multivariate/ 
univariate) 
p = 0.46/0.08, 
p = 0.55/0.04     
Hiltunen et al. [32] 207 ACY3 ^ Systolic BP ^ 
de Groote et al. [23] 130 ADRB1 Ser49Gly ∆LVEF (%) Data not 
shown  
130 ADRB1 Arg389Gly  Data not 
shown  
130 ADRB2 Gly16Arg  Data not 
shown  
130 ADRB2 Gln27Glu  Data not 
shown  
130 ADRB2 Thr164Ile  Data not 
shown 
Bruck et al. [42] 18 ADRB1 Arg389Gly ∆HR (BEATS/MIN) p < 0.05     
∆Systolic BP (mmHg) p < 0.05     
∆Diastolic BP (mmHg) p > 0,05     
∆PRA (plasma renin activity) p < 0.05 
de Groote et al. [43] 130 ACE ACE I/D ∆LVEF Data not 
shown 
Gong et al. [44] 207 PTPRD 11018077C > A Ambulatory diastolic BP p = 0095  
207 OTOL1 161760608A > G BP response p = 0,65 
Suonsyrja et al. [16] 208 ADRB1 Ser49Gly Ambulatory BP (Systolic/diastolic) p = 0,10/ 
p = 0,18     
Office BP (Systolic/diastolic) 
(continued on next page) 
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Four of them [16,32,40,41] are derived from the study “GENRES 
(Genetic of drug responsiveness in essential hypertension study): A 
randomized, double-blind, crossover, placebo-controlled trial based on a 
population of hypertensive Finnish men”. Another one replicates the 
results obtained from a previous genome-wide association study 
(GWAS) of atenolol, in the Finnish population of GENRES treated with 
bisoprolol [32]. One article reports the results of a double-blinded, 
placebo-controlled, multi-center clinical trial of a CAD population un-
dergoing surgery with neuraxial blockade, with the aim to explore the 
benefits of perioperative bisoprolol administration on MACE [21]. Two 
articles are from a prospective single center study of HF patients that 
started β-blocker therapy in the period of time selected by authors [23, 
43]. Another one is based on a sample of patients from the “Cardiac 
Insufficiency Bisoprolol Study in Elderly study (CIBIS-ELD): a random-
ized double-blinded study of bisoprolol and carvedilol in HF patients” 
[22]. One more article is also based on HF patients with bisoprolol in 
Korean population [39]. One of the two articles left is a single-center 
study in Yakutsk (Russia) of patients with CAD treated with various 
β-blockers and the last one is a single-center study of patients with any 
cardiovascular disease treated with bisoprolol [37,38]. 
3.1. Research articles about bisoprolol association with genetic 
polymorphisms in ADRB genes 
Zaugg et al. [21] explored whether bisoprolol would protect patients 
at risk of cardiovascular complications undergoing surgery with spinal 
block in Swiss patients with CAD after 12 months follow-up, including 
genetic polymorphisms in the ADRB1/ADRB2 genes as possible de-
terminants of bisoprolol efficacy. These authors found that bisoprolol is 
not useful in terms of security in these patients, but they found that 
ADRB1 Arg389Gly SNP is predictor of better response to bisoprolol 
(p = 0,01; see Table 2). 
Lee et al. [39] studied in patients with chronic HF the same variants 
in ADRB2 and ADRB1 than Zaugg et al. except the ADRB1 (rs1801252). 
Their results showed that ADRB1 Arg389Arg genotype group needed 
higher doses of bisoprolol compared to Gly carriers (Arg389Gly, 
Gly389Gly genotypes) without differences in heart rates across geno-
types after treatment, suggesting the potential of individually tailoring 
β-blocker therapy according to ADRB1 genotype. 
Rau et al. as well, searched for associations within ADRB1 variants 
(rs1801252, rs1801253) in elderly HF patients treated with bisoprolol 
or carvedilol [22], but no association was observed about the influence 
of these genetic variants on heart lowering in patients treated with 
bisoprolol. They also genotyped the nine most frequent SNPs in CYP2D6 
but none of them were associated with response to both drugs and 
neither with the effect in HR [28]. 
De Groote et al. studied the association of 5 SNPs in ADRB1 
(rs1801252, rs1801253) and ADRB2 (rs1042713, rs1042714, 
rs1800888) with bisoprolol effect on LVEF, HR and BP in chronic HF 
patients [23]. There were no differences by genotype in those outcomes. 
They also searched for any association in those patients treated with 
carvedilol without success [43]. 
Bruck et al. [42] studied the ADRB1 rs1801253 variant in a small 
cohort of patients to explore the effects of bisoprolol in HR, BP and 
plasma-renin activity (PRA) after an infusion of dobutamine and its 
relationship with the genetic polymorphism. They found this variant as a 
determinant not only of hemodynamic effects but also of PRA, 
concluding that ADRB1 polymorphisms may be useful for predicting 
therapeutic responses to β-blocker treatment. 
Finally, Sounsyrja et al. [16] studied the four same variants as Zaugg 
et al. [21] in the ADRB1 and ADRB2 genes in hypertensive men. 
Regarding rs1801253 ADRB1 Arg389Gly, their results showed that pa-
tients with Gly389Gly genotype had a tendency in better BP response to 
bisoprolol compared with those Arg389Arg genotypes, but their results 
were not statistically significant [16]. 
3.2. Research articles about bisoprolol association with genetic 
polymorphisms in CYP2D6 
Regarding polymorphisms in CYP2D6, Rau et al. [22] genotyped the 
nine most frequent SNPs in CYP2D6 but none of them were associated 
with response to both drugs and neither with the effect in HR. 
On the other hand, Alkreathy et al. [37] investigated the rs1080985 
(CYP2D6*2A) and rs1065852 (CYP2D6*10) measuring bisoprolol 
plasma levels and blood pressure. They reported that CYP2D6*2A CC 
genotype carriers had higher BP (systolic and diastolic) and lower 
bisoprolol concentration (ng/mL) compared to GG or GC. They also 
reported higher frequencies of side effects such as tiredness, chest pain 
or troubled breathing in GG allele carriers. For the rs1065852 
(CYP2D6*10) all patients were homozygous (GG) [37]. 
Also, Fedorinov et al. studied the rs3892097 (CYP2D6*4) and 
rs1065852 (CYP2D6*10) in patients with CAD titrating dose of biso-
prolol [38]. For both SNPs, none of the patients carried the homozygous 
recessive genotypes. Their results showed that patients heterozygous for 
both variants received statistically significant lower dose of bisoprolol 
than those patients carrying the wildtype genotype for both SNPs. Also, 
the dose titrated of bisoprolol was lower in patients carrying the het-
erozygote genotype of rs3892097 (CYP2D6*4) [38]. 
Table 2 (continued ) 
Study n Gen SNP (Location) Related endpoint p-valor 
p = 0,45/ 
p = 0,86  
208 ADRB1 Arg389Gly ABP (Systolic/diastolic) p = 0,07/ 
p = 0,02     
Office BP (Systolic/diastolic) p = 0,78/ 
p = 0,80  
208 ADRB2 Gly16Arg Ambulatory BP (Systolic/diastolic) p = 0,42/ 
p = 0,43     
Office BP (Systolic/diastolic) p = 0,49/ 
p = 0,50  
208 ADRB2 Gln27Glu Ambulatory BP (Systolic/diastolic) p = 0,96/ 
p = 0,94     
Office BP (Systolic/diastolic) P = 0,75/ 
P = 0,49 
refSNP: Reference single nucleotide polymorphism; MAF: Minor Allele Frequency; mm: number of patients with recessive homozygous genotype; Mm: Heterozygous 
genotype; MM: Dominant homozygous genotype; CD: Cardiac Disease. +Only shows parameters with p-value < 0.5 for the association with the genetic variant or 
included in the meta-analysis. *Only shows genes with statistically significant related results, see the original publication to know all the studied genes and variants. 
^Several SNPs were studied, see results in the original publication. 
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3.3. Research articles about bisoprolol association with polymorphisms in 
non-ADRB genes 
Sounsyrja et al. have also studied other genetic variants in genes 
related to cardiovascular diseases. In the same cohort of hypertensive 
men, they explored the effect of angiotensin gene (AGT) Met235Thr 
(rs699), angiotensin converting enzyme (ACE) insertion/deletion (I/D), 
angiotensin II type I receptor (AGTR1) 1166A/C (3 prime UTR variant) 
(rs5186), and α-adducin (ADD1) Gly460Trp (rs4961) polymorphism on 
BP response to bisoprolol. There were no association between these 
polymorphisms with BP responses, just for ADD1 Gly460Trp (rs4961) 
the ambulatory systolic BP was barely lower in patients carrying the Trp 
allele, but the difference was not statistically significant [40]. De Groote 
et al. also analyzed the impact of ACE gene deletion in LVEF in HF pa-
tients, but they did not found differences between genotypes [43]. 
Donner et al. tried to identify more SNPs that could affect the BP 
response to four antihypertensive treatments including bisoprolol in the 
population of hypertensive men of GENRES. None of these gene variants 
reached a significant level of association stablished (p < 0.0007), but 
two of them (rs17367504 and rs11014166) showed a tendency in 
genotype-related differences (p < 0.05). Only the rs6749447 variant in 
STK39 gene was associated with BP response to losartan [41]. 
For the same population of GENRES, Hiltunen et al., conducted a 
GWAS to identify SNPs affecting the response to four antihypertensive 
drugs. They identified the 20 different genetic loci with the lowest P 
values for BP response for each drug, considering significant values P 
values < 5 × 10-8. Three SNPs (rs2514036, rs948445 and rs2514037) 
showed evidence for association with ambulatory systolic BP changes 
after bisoprolol. These SNPs are related with the ACY3 gene coding for 
aminoacylase III. They also performed a meta-analysis of the 20 SNPs 
associated with bisoprolol response, in the population of the PEAR 
study, treated with atenolol, to asses any association with this β-blocker. 
Only one out of two SNPs with suggestive evidence of association for 
both drugs, the rs7268800, is located close to a protein-coding gene, the 
SPATA13 gene, which codes for a protein associated with spermato-
genesis [32]. Finally, Gong et al. explored the association of two SNPs 
(intergenic variants) in PTPRD (rs12346562) and OTOL1 genes 
(rs7640608), previously associated with response to atenolol in PEAR 
patients, in GENRES patients. Only the PTPRD SNP showed some indi-
cation of genotype differences in diastolic BP response to bisoprolol 
(p = 0.095) in trend with findings for atenolol (A allele carriers respond 
better to the β-blocker effect) [44]. 
3.4. Meta-analysis 
Among the considered publications after systematic review, the 
ADRB1 A389G (rs1801253) was the only variant assessed for the asso-
ciation with bisoprolol response in at least two publications and it was 
the only one related to an endpoint feasible enough to be compared (see 
Tables 1 and 2). We performed a meta-analysis about the association of 
ADRB1 A389G with bisoprolol response, considering as endpoint, first, 
the mean systolic BP, and second, the mean diastolic BP. Systolic and 
diastolic BP were recorded in baseline and follow-up time for each of the 
included publications, and, mean change and SD were calculated. We 
included in the meta-analysis 3 publications among all those found in 
the systematic review. 
About the influence of ADRB1 A389G variant on systolic BP in pa-
tients treated with bisoprolol we did not find statistically significant 
results for both the dominant model (SMD = 0.02; 95% CI = − 0.13 to 
0.17; p-value = 0.98) and the recessive genetic model (SMD = 0.05; 
95% CI = − 0.31 to 0.41; p-value = 0.98). This also happened for the 
association with diastolic BP for both the dominant (SMD = 0.04; 95% 
CI = − 0.15 to 0.23; p-value = 0.97) and recessive genetic model 
(SMD = 0.10; 95% CI = − 0.69 to 0.89; p-value = 0.91). As we can see 
(Figs. 3 to 6), our results show a high statistical homogeneity (I2 = 0%). 
4. Discussion 
To our knowledge, this is the first systematic review performed about 
genetic variants affecting bisoprolol response. Clearly, the most genetic 
variants assessed to be associated with bisoprolol response are in ADRB1 
and ADRB2. 
The main limitation of this systematic review and meta-analysis is 
related to main results. We found only 13 articles after systematic review 
and three of them only were available to be included in the meta- 
analysis. Also, related to the methodology, we excluded publications 
not written in English (n = 65; see Fig. 2), since it would be difficult to 
find official translators to several languages in those manuscripts and all 
of them were published in low impact factor scientific journals. 
Furthermore, research articles from Suonsyrja et al. [16] Rau et al. [22] 
included in the meta-analysis, provided not combinable results so they 
were contacted in order to provide means values and SD by genotype in 
baseline and follow-up time in order to perform the meta-analysis. In 
this regard, it is important to highlight the heterogeneity of populations 
recruited in included publications (see Tables 1 and 2). As we can see, 
different ethnicities, indication of use, follow-up times and endpoints 
were considered. 
These limitations mean the need of perform further studies assessing 
the influence of genetic variants on bisoprolol response, including 
multivariant analysis considering different populations, indications of 
use, other clinical parameters and/or previously known genetic poly-
morphisms influencing bisoprolol response. Even, it would be inter-
esting to look for new or low frequency genetic variants that may be 
influencing the response to the drug using newer methodologies as 
“Next Generation Sequencing” (NGS) technologies or “Genome Wide 
Association Studies” (GWAS). 
Among genetic variants assessed to be associated with bisoprolol 
response, the ADRB1 Arg389Gly polymorphism is by large the most 
studied among polymorphism related with β-blockers but its influence 
on bisoprolol response remains unclear. 
Bibliography suggests an association between this variant and biso-
prolol response regardless of the illness, but in our meta-analysis we did 
not find an association about ADRB1 Arg389Gly and change in systolic 
BP or diastolic BP. This may be explained by multiple circumstances as 
Fig. 3. Forest plot of the meta-analysis showing the association between ADRB1 A389G (rs1801253) and treatment response to bisoprolol (systolic blood pressure) 
using random-effects models. Dominant model. 
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the heterogeneity in the studied population by publication, the specific 
effect of bisoprolol on systolic BP and diastolic BP etc. 
This probes the need of further studies in this regard. 
4.1. Bisoprolol and ADRB genetic polymorphisms 
About the studied SNPs in ADRB1 gene, Zaugg et al. [21] found an 
association between the ADRB1 arg389gly and the composed primary 
outcome of cardiovascular mortality/nonfatal myocardial infarctio-
n/unstable angina/congestive HF/cerebrovascular accident (CVA) (H. 
R. = 1,87; 95%CI = 1,04–3,35; p-value = 0,04), concluding that ADRB1 
genotype, but not perioperative bisoprolol, may determine cardiovas-
cular outcome in at-risk patients undergoing surgery with spinal block. 
Looking carefully at these results we found that considering patients 
treated with bisoprolol only, these results remain statistically signifi-
cant. Zaugg et al. reported the following primary outcome distribution 
among patients treated with bisoprolol: 8 of 55 [14.5%] with ADRB1 
wildtype genotype, and 14 of 37 [37.8%] patients carrying the ADRB1 
arg389gly SNP; this means O.R. = 3.58; 95% CI = 1.18–11.21; p-val-
ue = 0.01). This might mean a significant association between the 
ADRB1 Arg389Gly variant and bisoprolol response. Also, Lee et al. [39] 
suggested that tailoring bisoprolol dose depending on ADRB1 genotype 
may lead to less adverse events such as bradycardia [39]. 
On the other hand, results from Rau et al. [22] did not find a sta-
tistically significance about the influence of ADRB1 polymorphisms and 
bisoprolol response, and highly suggest that the clinical effect of these 
polymorphisms varies between β-blockers, this way among Arg389Arg 
genotype patients with atrial fibrillation, Rau et al. described differences 
in HR lowering effect comparing carvedilol vs. bisoprolol. A limitation 
of their study is that 60% of the patients had been previously treated 
with a β-blocker, thus, they might be resistant to carvedilol or bisoprolol. 
And, as well, they could not explore the combined effects of different 
ADRB variants. In an in vitro study authors described that the arginine 
form in ADRB1 had enhanced coupling to Gs, producing more cAMP 
signal mediated by the adenylyl cyclase, which leads to more active 
receptors available. This suggests that physiologic differences in the 
polymorphism may be the basis of the huge interindividual variation in 
response to β-blockers [45]. 
As commented above, results from Sounsyrja et al. showed a ten-
dency in better BP response in patients Ser49Ser homozygotes 
(rs1801252) compared with Ser49Gly heterozygotes, but results were 
inconclusive [16]. 
About ADRB2 gene polymorphisms, previous studies revealed that 
Glu27 polymorphism (rs1042714) and Arg16 (rs1042713) are more 
resistant to down-regulation and, in consequence, these variants might 
be more sensible to the effect of β-blockers. Even though, none of the 
authors found associations with response to bisoprolol and variants in 
ADRB2 gene [25]. 
Anyway, as we can see, there is an important heterogeneity about 
how genetic polymorphisms in ADBR genes influence the response to 
Fig. 4. Forest plot of the meta-analysis showing the association between ADRB1 A389G (rs1801253) and treatment response to bisoprolol (systolic blood pressure) 
using random-effects models. Recessive model. 
Fig. 5. Forest plot of the meta-analysis showing the association between ADRB1 A389G (rs1801253) and treatment response to bisoprolol (Diastolic blood pressure) 
using random-effects models. Dominant model. 
Fig. 6. Forest plot of the meta-analysis showing the association between ADRB1 A389G (rs1801253) and treatment response to bisoprolol (Diastolic blood pressure) 
using random-effects models. Recessive model. 
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bisoprolol. Based on results from research articles found in this sys-
tematic review, the ADRB1 Arg389Gly variant seems to be the most 
relevant on the influence over bisoprolol response regardless of the 
pathology. But we can find contradictory results depending on the 
clinical parameter considered as endpoint, population etc. Also, when 
we performed a meta-analysis, we did not find either significant results. 
4.2. Bisoprolol and other genetic polymorphisms 
Mohammed Alkreathy et al. [37] and Fedorinov et al. [38], explored 
genetic variants in gene enconding CYP2D6 isozyme but we cannot 
consider their results consistent as in both samples of patients for the 
SNPs analyzed the heterozygote or homozygote allele was not present. 
Other limitation of their studies is that they did not analyze the influence 
of variants in CYP3A4, while bisoprolol is principally metabolized by 
this CYP isoform. 
The ACE insertion/deletion (I/D) genetic polymorphism has been 
investigated in PGx studies of antihypertensive drugs but, as described 
by Sounsyrja et al. [40] and de Groote et al. [43] it has not been asso-
ciated with BP response to different classes of drugs such as β-blockers, 
thiazides or ACE inhibitors and it does not seem to be determinant in 
response or safety of β-blockers. 
Results reported by Donner et al. suggest that other SNPs 
(rs17367504, rs6749447) may be implicated in the action of bisoprolol 
in hypertensive men, that need to be studied profoundly in large pop-
ulation studies to determine their connotation [41]. One of these SNPs, 
rs6749447 in STK39 gene, is notably associated with response to los-
artan in this study. This gene encodes a serine threonine kinase that 
regulates the activity and expression of various renal ions 
co-transporters that modulate the homeostasis; thus, it has a relevant 
function in hypertension [46,47]. More SNPs possibly associated with 
BP regulation in hypertension are located in ACY3, ALDH3B2, PTPRD 
and OTOL1, that need to be studied profoundly to really asses any 
relevant PGx association in response to bisoprolol [32,44]. 
5. Conclusions 
In conclusion, most of β-blockers such as bisoprolol, metoprolol, 
atenolol, carvedilol etc.; share indication of use, have similar pathways 
and mechanisms of action, and bisoprolol use is even more frequent 
depending on the sanitary system. Despite these similarities, for meto-
prolol, several pharmacogenetic studies have been performed, its drug 
label includes pharmacogenetic information, there are available phar-
macogenetic dossing guidelines and there are warnings from sanitary 
authorities in this regard. 
By contrast, there is an important lack of studies about the influence 
of genetic polymorphisms on other β-blockers (bisoprolol, atenolol, 
carvedilol etc.) response. 
Regarding bisoprolol, we found only 13 publications studying the 
association of genetic polymorphisms with patientś response to treat-
ment, and even though the ADRB1 Arg389Gly variant seems to have an 
influence on bisoprolol efficacy, published results are inconclusive and 
our meta-analysis did not find a statistically significant results in this 
regard. 
This systematic review supports the need of research in this field, 
assessing how different genetic variants, especially in ADRB and 
CYP2D6 genes may influence bisoprolol response. This should be studied 
considering different indications of use, interactions between genetic 
variants and multiple clinical parameters, use of co-medications and 
other co-morbidities. 
Funding 
This research did not receive any specific grant from funding 
agencies in the public, commercial, or not-for-profit sectors. 
CRediT authorship contribution statement 
Celia Castaño-Amores: Conceptualization, Methodology, Writing – 
original draft, Investigation, Resources, Visualization. Xando Díaz- 
Villamarín: Conceptualization, Methodology, Writing – original draft, 
Investigation, Resources, Visualization. Ana María Pérez-Gutiérrez: 
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